This article is more than 5 years old. Information may no longer be current.

Anti-VEGF may be useful for highly myopic choroidal neovascularization

Graefes Arch Clin Exp Ophthalmol. 2010;248(7):937-941.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Anti-VEGF injections appear to be effective in the management of subfoveal and juxtafoveal choroidal neovascularization secondary to high myopia, but visual gains decreased to insignificant levels at the end of a 2-year study.

In 19 highly myopic eyes of 18 patients with subfoveal or juxtafoveal CNV treated with three monthly doses of Avastin (bevacizumab, Genentech) in a nonrandomized, interventional case series, mean best corrected visual acuity improved from 0.54 logMAR at baseline to 0.40 logMAR at 1 year (P = .04). However, at the 2-year follow-up point, mean BCVA had regressed slightly to 0.47 logMAR, and the difference from baseline was no longer statistically significant.

According to the study, patients were evaluated monthly for change in BCVA and for structural change on optical coherence tomography. Four eyes required re-treatment during the first year and four eyes received a second injection during the second year of the study.

"Neither ocular nor systemic adverse reactions were detected," the study authors wrote.

Follow OSNSuperSite.com on Twitter.